120 related articles for article (PubMed ID: 30047001)
1. Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
Rahmani MR; Shamsizadeh A; Hakimizadeh E; Allahtavakoli M
Inflammation; 2018 Dec; 41(6):2052-2059. PubMed ID: 30047001
[TBL] [Abstract][Full Text] [Related]
2. Monoacylglycerol lipase inhibitor, JZL-184, confers neuroprotection in the mice middle cerebral artery occlusion model of stroke.
Rahmani MR; Shamsizadeh A; Moghadam-Ahmadi A; Kaeidi A; Allahtavakoli M
Life Sci; 2018 Apr; 198():143-148. PubMed ID: 29496497
[TBL] [Abstract][Full Text] [Related]
3. JZL184, as a monoacylglycerol lipase inhibitor, down-regulates inflammation in a cannabinoid pathway dependent manner.
Rahmani MR; Shamsizadeh A; Moghadam-Ahmadi A; Bazmandegan G; Allahtavakoli M
Biomed Pharmacother; 2018 Jul; 103():1720-1726. PubMed ID: 29864962
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
[TBL] [Abstract][Full Text] [Related]
5. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke.
Yu S; Liu X; Shen Y; Xu H; Yang Y; Ding F
Neuroscience; 2016 Jul; 327():44-52. PubMed ID: 27060484
[TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Copin JC; Bengualid DJ; Da Silva RF; Kargiotis O; Schaller K; Gasche Y
Eur J Neurosci; 2011 Oct; 34(7):1085-92. PubMed ID: 21895804
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
9. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Shimada Y; Shimura H; Tanaka R; Yamashiro K; Koike M; Uchiyama Y; Urabe T; Hattori N
PLoS One; 2018; 13(5):e0198039. PubMed ID: 29795667
[TBL] [Abstract][Full Text] [Related]
11. The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents.
Sakin YS; Dogrul A; Ilkaya F; Seyrek M; Ulas UH; Gulsen M; Bagci S
Neurogastroenterol Motil; 2015 Jul; 27(7):936-44. PubMed ID: 25869205
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
Tan Z; Li X; Turner RC; Logsdon AF; Lucke-Wold B; DiPasquale K; Jeong SS; Chen R; Huber JD; Rosen CL
Eur J Pharmacol; 2014 Sep; 738():368-73. PubMed ID: 24933645
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting 12/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models.
Karatas H; Eun Jung J; Lo EH; van Leyen K
Brain Res; 2018 Jan; 1678():123-128. PubMed ID: 29079502
[TBL] [Abstract][Full Text] [Related]
15. Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke.
Dela Peña IC; Yang S; Shen G; Fang Liang H; Solak S; Borlongan CV
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857523
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal Stem Cells: The Potential Therapeutic Cell Therapy to Reduce Brain Stroke Side Effects.
Shabanizadeh A; Rahmani MR; Yousefi-Ahmadipour A; Asadi F; Arababadi MK
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105668. PubMed ID: 33631477
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
19. Interferon-β modulates microglial polarization to ameliorate delayed tPA-exacerbated brain injury in ischemic stroke.
Kuo PC; Weng WT; Scofield BA; Paraiso HC; Bojrab P; Kimes B; Yu II; Yen JJ
Front Immunol; 2023; 14():1148069. PubMed ID: 37063896
[TBL] [Abstract][Full Text] [Related]
20. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Nakano T; Irie K; Hayakawa K; Sano K; Nakamura Y; Tanaka M; Yamashita Y; Satho T; Fujioka M; Muroi C; Matsuo K; Ishikura H; Futagami K; Mishima K
Brain Res; 2015 Oct; 1624():330-335. PubMed ID: 26254727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
